Stockscreener 앱 받기
4.26
13.75%
0.515
시간 외 거래:
4.35
0.09
+2.11%
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
RSU vesting boosts Iovance (NASDAQ: IOVA) CRO share holdings - Stock Titan
Iovance Biotherapeutics (NASDAQ:IOVA) Trading 9.9% Higher After Analyst Upgrade - MarketBeat
Iovance Biotherapeutics’ TIL Therapy Showcases Promising Results - StocksToTrade
Iovance Biotherapeutics: Short-Term Pain, Long-Term GainI'm Still Bullish After All These Years - Seeking Alpha
Iovance Biotherapeutics’ Stock Rallies After Promising Trial Data - timothysykes.com
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Citizens Upgrades Iovance Biotherapeutics (IOVA) - Nasdaq
Assessing Iovance Biotherapeutics (IOVA) Valuation After Amtagvi Momentum And New Fast Track Designation - Sahm
IOVA Receives Analyst Upgrade to Market Outperform by Citizens | - GuruFocus
Citizens Jmp Upgrades Iovance Biotherapeutics (NASDAQ:IOVA) to "Market Outperform" - MarketBeat
A Glimpse Into The Expert Outlook On Iovance Biotherapeutics Through 4 Analysts - Benzinga
This Unity Software Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday - Benzinga
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Short Interest Up 24.8% in February - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Gains Visibility Across The Nasdaq Index - Kalkine Media
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
IOVA: AMTAGVI drives robust growth as pipeline advances toward major milestones in lung and sarcoma - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Iovance Lifileucel Progress Reshapes Growth Prospects Beyond Melanoma - Yahoo Finance
IOVA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Why Iovance Biotherapeutics (IOVA) Is Up 34.5% After Amtagvi-Fueled Revenue Jump And Lifileucel Fast Track - Sahm
Wall Street Zen Upgrades Iovance Biotherapeutics (NASDAQ:IOVA) to Hold - MarketBeat
Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Potential Upside of 132% Amid Rising Investor Interest - DirectorsTalk Interviews
Is Iovance Biotherapeutics (IOVA) Pricing Reflect Recent Cell Therapy Progress Accurately - Yahoo Finance
IOVA Should I Buy - Intellectia AI
Iovance (NASDAQ: IOVA) CCO vests 120,000 PSUs, withholds shares for tax - Stock Titan
Iovance Biotherapeutics (IOVA) Reports 61% Annual Revenue Growth Driven by Amtagvi Success - Yahoo Finance
Strategic Milestones Propel Iovance Biotherapeutics Inc. - StocksToTrade
Iovance Biotherapeutics to Present at Upcoming Conferences - ChartMill
Brokers Set Expectations for IOVA Q1 Earnings - MarketBeat
Guidance Update: Whats the beta of Iovance Biotherapeutics Inc stockQuarterly Profit Report & Smart Swing Trading Techniques - baoquankhu1.vn
1 Nearly Unknown Biotech Stock Set To Go Parabolic If Its Pipeline Hits - AOL.com
IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress - The Globe and Mail
Iovance Highlights Amtagvi Revenue Growth and Profitability Path - The Globe and Mail
Key facts: Iovance's Lifileucel gains Fast Track; Barclays raises target to $11 - TradingView
Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why - Yahoo Finance
Iovance Biotherapeutics (IOVA) Analyst Raises Price Target to $1 - GuruFocus
Iovance Biotherapeutics Surges Amid Encouraging Sarcoma Therapy Data - timothysykes.com
Barclays Boosts Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $11.00 - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Sees Strong Trading Volume Following Earnings Beat - MarketBeat
Iovance Biotherapeutics TIL Therapy Shows Promising Upside - StocksToTrade
Chardan Capital Has Lowered Expectations for Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Raised to Market Outperform at Citizens Jmp - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2025 Earnings Call Transcript - Insider Monkey
IOVA Stock Upgraded to Market Outperform by Citizens Analyst | I - GuruFocus
Iovance Biotherapeutics stock rating upgraded on revenue growth By Investing.com - Investing.com Canada
Iovance Biotherapeutics Q4 Loss Narrows To US$0.18 EPS And Tests Bearish Narratives - simplywall.st
Iovance Biotherapeutics stock rating upgraded on revenue growth - Investing.com
Iovance Biotherapeutics Reports Record Q4 Margins and Strong Upside Potential - Intellectia AI
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
Iovance Biotherapeutics Inc (IOVA) Q4 2025 Earnings Call Highlig - GuruFocus
Decoding Iovance Biotherapeutics Inc (IOVA): A Strategic SWOT In - GuruFocus
Iovance FDA Approval Shifts Lifileucel From Pipeline Bet To Execution Test - Yahoo Finance
Iovance Biotherapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Iovance Biotherapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Iovance (IOVA) Q4 2025 Earnings Call Transcript - AOL.com
Iovance Biotherapeutics: Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade) - Seeking Alpha
Iovance Biotherapeutics (IOVA) Reports Strong Q4 2025 Growth - GuruFocus
Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy - Benzinga
A Look At Iovance Biotherapeutics (IOVA) Valuation After Encouraging Amtagvi Data And Lung Cancer Fast Track Status - Yahoo Finance
Iovance stock surges 32% on positive sarcoma trial data - Investing.com Australia
Iovance Biotherapeutics Q4 Earnings Call Highlights - MarketBeat
Iovance Biotherapeutics Sees Unusually High Options Volume (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics (IOVA) Surges 26% on Strong Q4 and Promi - GuruFocus
Why Iovance Biotherapeutics (IOVA) Is Up 12.5% After Amtagvi-Fueled Q4 Beat And Narrower Loss - Yahoo Finance
Iovance surges on Q4 results, Amtagvi data in soft tissue sarcoma - Seeking Alpha
Iovance Biotherapeutics Rises 25% On Positive Sarcoma TIL Data And Strong FY25 Results - RTTNews
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Up on Better-Than-Expected Earnings - MarketBeat
0.11%
6.00%
자본화:
|
볼륨(24시간):